NCT05048017 Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma Status RECRUITING Phase PHASE2
NCT05025592 cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC Status UNKNOWN Phase N/A
NCT04985136 A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) Status TERMINATED Phase PHASE3
NCT04879368 RegoNivo vs Standard of Care Chemotherapy in AGOC Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04874207 Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib Status COMPLETED Phase PHASE4
NCT04787341 PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04781192 The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04776148 Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) Status COMPLETED Phase PHASE3
NCT04771715 Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer Status UNKNOWN Phase N/A
NCT04757363 A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04718909 Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC Status UNKNOWN Phase PHASE2
NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. Status COMPLETED Phase PHASE1/PHASE2
NCT04625907 FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma Status RECRUITING Phase PHASE1/PHASE2
NCT04534218 Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer Status COMPLETED Phase PHASE2
NCT04431791 Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer Status UNKNOWN Phase N/A
NCT04362839 Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Status COMPLETED Phase PHASE1
NCT04327700 Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib Status TERMINATED Phase PHASE2
NCT04200404 A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT04170556 Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) Status COMPLETED Phase PHASE1/PHASE2
NCT04117945 Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2